Travel Time to Tanning Facilities Negatively Linked to Melanoma Incidence
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 7, 2024 -- There is a negative association between travel time to tanning facilities and county-level melanoma incidence rates, according to a study published online Nov. 7 in the Journal of Investigative Dermatology.
Guixing Wei, Ph.D., from Brown University in Providence, Rhode Island, and colleagues examined the association between melanoma incidence and access to tanning bed facilities using data for New England county-level melanoma incidence rates for 2014 to 2018, tanning bed facilities location, demographic data, socioeconomic data, and geographic data.
The researchers found that for every one-minute increase in average travel time to tanning facilities within a 30-minute travel time threshold, there was a decrease in melanoma incidence by 3.46 and 1.92 percent in the same county and across New England, respectively. A negative association was identified between average travel time to tanning facilities and county-level melanoma incidence rate. With respect to county-level melanoma rate, six high-risk clusters and seven low-risk clusters were identified.
"The identification of clusters of melanoma incidence can help inform the strategic targeting of interventions and resources that aim to reduce the burden of melanoma," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Presurgical Immunotherapy Offers Long-Term Benefit in Melanoma
FRIDAY, July 18, 2025 -- Neoadjuvant systemic treatment (NST) followed by adjuvant treatment with nivolumab and relatlimab offers long-term benefit in adults with stage III/IV...
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
FRIDAY, July 11, 2025 -- The introduction of immune checkpoint inhibitors (ICIs) was associated with a widening survival disparity between those with private insurance and those...
AI Better for Tumor-Infiltrating Lymphocyte Quantification in Melanoma Than Traditional Methods
TUESDAY, July 8, 2025 -- For tumor-infiltrating lymphocyte (TIL) quantification in melanoma, an artificial intelligence (AI) algorithm demonstrates superior reproducibility and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.